Our therapeutic area ..
To date, about ten drugs make up Mealitech's offer of care in the fields of cancer, gastrointestinal and hematology, kidney, rheumatism and cardiovascular.About twenty molecules are under clinical development, half onco hematology and the other half on kidney / internal medicine.
Clinical research is particularly active at Mealitech.
In 2018, 54 positive studies involving 1,138 patients at nearly 350 locations across France.
This puts the French subsidiary among the countries in the world where Mealitech has the largest clinical research activity.
QUESTRANS
(colestyramine) (exploitation transférée aux Laboratoires QUESTPHARM depuis le 01/10/2019)
MUCOMYSTEND
(acétylcytéine) (exploitation transférée aux Laboratoires MUCOMYSPHARM depuis le 17/12/2018)
LACBIO MAX
(Biologic Medicines)
(exploitation transférée aux Laboratoires MEALITECHPHARM depuis le 10/03/2019)
The product has been commercialized by Mealitech from 01/2020.
Registered No: EUR-F5122-06481 3795122064814
ETOPOPHO
(étoposide de phosphate) (exploitation transférée aux Laboratoires ETOPOPHARM depuis le 30/06/2019)
FUNGIZON
(amphotéricine B) (exploitation transférée aux Laboratoires FUNGIPHARM depuis le 01/03/2020)